Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

Summary

This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic impairment) and participants with normal hepatic function as healthy control.

Timeline

Start

2021-09-07

Primary completion

2022-05-12

Completion

2022-05-12

Drugs

Indications